Raddeanin A is associated with enhanced anti-tumor efficacy of doxorubicin in a murine breast cancer model by modulating MDR1 expression
Abstract
BackgroundDoxorubicin (DOX) efficacy in breast cancer is limited by multidrug resistance (MDR) associated with P-gp/MDR1. Raddeanin A (RA) shows antitumor potential, but its role in modulating MDR is unexplored.PurposeTo evaluate whether RA may potentiate DOX anticancer effects and to examine potential mechanisms potentially involving MDR1-associated efflux.MethodsSynergy was assessed in 4T1 cells (MTT, colony formation, apoptosis, ROS, Nrf2/HO-1). Molecular docking and flow cytometry evaluated RA-MDR1 interaction and DOX accumulation. In vivo efficacy and cardiotoxicity were examined in a 4T1 xenograft model.ResultsRA was associated with DOX sensitivity (reduced IC50), synergistically suppressed proliferation, increased ROS/apoptosis, and was associated with downregulation of Nrf2/HO-1 expression levels. Mechanistically, RA was associated with reduced MDR1 expression and increased intracellular DOX accumulation, consistent with the possibility that RA may be associated with altered drug retention potentially related to MDR1. In vivo, RA + DOX combination was associated with improved tumor inhibition without additional systemic or cardiotoxicity (normal body weight, cardiac histology, CK/CK-MB). This was associated with enhanced apoptosis and reduced MDR1 expression, along with findings consistent with reduced Nrf2/HO-1 expression levels in tumors.ConclusionOur findings suggest that RA may be associated with reduced MDR1 expression and increased intracellular DOX accumulation, increased apoptotic signaling, and downregulation of Nrf2/HO-1 expression levels, as suggested by correlative and pharmacological data. These observations are consistent with the possibility that RA may serve as a potential adjuvant to improve DOX efficacy in breast cancer, although further mechanistic studies are required to establish causality.
Related
- Zhuyu pill relieves cholestasis in rats by modulating the expression of lncRNAs and circRNAs
- The long noncoding RNA MAPKAPK5-AS1 promotes the formation of hepatitis B virus cccDNA by modulating the expression of NABP1.
- LncRNA A1BGAS1 Serves as a Tumor Suppressor in Non-Small Cell Lung Cancer by Modulating the Expression of miR-3942-5P.
- Kamishoyosan reduces anxiety-like behavior by modulating GABAA receptor subunit expression in a premenstrual syndrome rat model
- Phenolic-Rich Aronia melanocarpa (cv. Nero) Extract Attenuates Doxorubicin-Induced Nephrotoxicity Associated with Reduced Oxidative Stress, Inflammation, and Endoplasmic Reticulum Stress
BibTeX
@article{hui2026raddeanin,
title = {{Raddeanin A is associated with enhanced anti-tumor efficacy of doxorubicin in a murine breast cancer model by modulating MDR1 expression}},
author = {Lishan Hui and Nanding Wu and Qixuan Sun and Yunping Zhang and Haoyuan Zheng and Chunyu Ma and Jianhua Huang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1934305},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1934305},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Raddeanin A is associated with enhanced anti-tumor efficacy of doxorubicin in a murine breast cancer model by modulating MDR1 expression
AU - Lishan Hui
AU - Nanding Wu
AU - Qixuan Sun
AU - Yunping Zhang
AU - Haoyuan Zheng
AU - Chunyu Ma
AU - Jianhua Huang
PY - 2026
DA - 2026/11/04
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1934305
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1934305
AB - BackgroundDoxorubicin (DOX) efficacy in breast cancer is limited by multidrug resistance (MDR) associated with P-gp/MDR1. Raddeanin A (RA) shows antitumor potential, but its role in modulating MDR is unexplored.PurposeTo evaluate whether RA may potentiate DOX anticancer effects and to examine potential mechanisms potentially involving MDR1-associated efflux.MethodsSynergy was assessed in 4T1 cells (MTT, colony formation, apoptosis, ROS, Nrf2/HO-1). Molecular docking and flow cytometry evaluated RA-MDR1 interaction and DOX accumulation. In vivo efficacy and cardiotoxicity were examined in a 4T1 xenograft model.ResultsRA was associated with DOX sensitivity (reduced IC50), synergistically suppressed proliferation, increased ROS/apoptosis, and was associated with downregulation of Nrf2/HO-1 expression levels. Mechanistically, RA was associated with reduced MDR1 expression and increased intracellular DOX accumulation, consistent with the possibility that RA may be associated with altered drug retention potentially related to MDR1. In vivo, RA + DOX combination was associated with improved tumor inhibition without additional systemic or cardiotoxicity (normal body weight, cardiac histology, CK/CK-MB). This was associated with enhanced apoptosis and reduced MDR1 expression, along with findings consistent with reduced Nrf2/HO-1 expression levels in tumors.ConclusionOur findings suggest that RA may be associated with reduced MDR1 expression and increased intracellular DOX accumulation, increased apoptotic signaling, and downregulation of Nrf2/HO-1 expression levels, as suggested by correlative and pharmacological data. These observations are consistent with the possibility that RA may serve as a potential adjuvant to improve DOX efficacy in breast cancer, although further mechanistic studies are required to establish causality.
SN - 1663-9812
ER -